OCI-LY19 Cells

OCI-Ly19 is a human B-cell lymphoma cell line derived from the malignant lymph node of a patient with diffuse large B-cell lymphoma (DLBCL), a common and aggressive subtype of non-Hodgkin lymphoma. This cell line serves as a valuable tool for investigating the molecular mechanisms underlying DLBCL pathogenesis, including aberrant B-cell receptor (BCR) signaling, dysregulation of transcription factors, and genetic alterations driving tumor progression. OCI-Ly19 is frequently used in studies aimed at understanding DLBCL biology and developing targeted therapeutic strategies.

OCI-Ly19 cells exhibit typical B-cell morphology and grow in suspension under standard culture conditions. The cell line is characterized by chromosomal abnormalities and genetic alterations commonly associated with DLBCL, including those affecting the MYC oncogene and BCL-2 family members. These features make OCI-Ly19 an important model for studying oncogenic signaling pathways, such as the PI3K/AKT/mTOR and NF-κB pathways, which are critical for B-cell survival and proliferation in lymphoma. In addition, OCI-Ly19 cells express surface markers characteristic of mature B cells, making them suitable for exploring antigen receptor signaling and immune evasion mechanisms in lymphoma.

OCI-Ly19 is widely used in preclinical research to evaluate the efficacy of chemotherapeutic agents, monoclonal antibodies (e.g., anti-CD20 therapies), and small-molecule inhibitors targeting key signaling pathways. The cell line is also employed in drug resistance studies, particularly in the context of understanding mechanisms of relapse in DLBCL and identifying strategies to overcome treatment resistance. Its well-characterized genomic profile and relevance to DLBCL biology make OCI-Ly19 an indispensable resource for lymphoma research and therapeutic development.